张立博,邓婧,魏向龙

• 1:南方医科大学深圳医院心内科

摘要(Abstract)：

目的评价生物可吸收支架(bioresorbable vascular scaffold,BVS)在急性冠状动脉综合征(acute coronary syndrome,ACS)患者中临床应用的有效性和安全性。方法在线检索Pub Med、EMBase及the Cochrane library等数据库和美国心脏病学院、美国心脏协会及欧洲心脏病学会相关会议论文或摘要,以及一些相关专业网址(www.tctmd.com,www.crtonline.org和www.clinicaltrial.gov)等。根据纳入标准与排除标准筛选文献。结果的处理和统计分析通过Stata12.0软件实现。结果共提取7个研究,计2206例患者在相应的随访期间里可提取有效的临床终点事件数据。统计分析显示,BVS组与药物洗脱支架(drug eluting stent,DES)组相比,两组患者主要不良心血管事件(major adverse cardiovascular events,MACE)发生情况在随访时间分别为6个月、≥12个月、24个月时的差异均无统计学意义;心源性死亡率在随访时间分别为6个月、≥12个月、24个月时的差异均无统计学意义;两组间全因死亡、心肌梗死及靶病变再次血运重建发生率比较,差异均无统计学意义;BVS组总体血栓发生率与DES组相比,差异有统计学意义(2.1%比1.0%,RR 2.02,95%CI 1.01~4.06,P=0.034)。结论在ACS患者中置入BVS,与目前广泛使用的DES相比,MACE发生率、死亡率(心源性死亡及全因死亡)、心肌梗死及靶病变再次血运重建发生率均相当,但是BVS组血栓事件的发生率较高。受纳入研究数量和质量的限制,上述结论尚需开展更多高质量随机对照试验予以验证。

关键词(KeyWords)： 生物可吸收支架;药物洗脱支架;急性冠状动脉综合征;Meta分析

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张立博,邓婧,魏向龙

参考文献(References)：

• [1]Onuma Y,Serruys PW,Perkins LE,et al.Intracoronary optical coherence tomography and histology at 1 month and 2,3,and4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model:an attempt to decipher the human optical coherence tomography images in the ABSORB trial.Circulation,2010,122(22):2288-2300.
• [2]Serruys PW,Chevalier B,Dudek D,et al.A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions(ABSORB II):an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.Lancet.,2015,385(9962):43-54.
• [3]Ellis SG,Kereiakes DJ,Metzger DC,et al.Everolimus-Eluting bioresorbable scaffolds for coronary artery disease.N Engl J Med.,2015,373(20):1905-1915.
• [4]Gao R,Yang Y,Han Y,et al.Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease:ABSORB China trial.JACC,2015,66(21):2298-2309.
• [5]Cutlip DE,Windecker S,Mehran R,et al.Clinical end points in coronary stent trials:a case for standardized defi nitions.Circulation,2007,115(17):2344-2351.
• [6]Felix CM,Fam JM,Diletti R,et al.Mid-to long-term clinical outcomes of patients treated with the everolimus-eluting bioresorbable vascular scaffold:the BVS expand registry.JACC Cardiovasc Interv,2016,9(16):1652-63.
• [7]Kocka V,Maly M,Tousek P,et al.Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction:a prospective multicentre study'Prague 19'.Eur Heart J,2014,35(12):787-794.
• [8]Tousek P,Kocka V,Maly M,et al.Two-year follow-up after bioresorbable vascular scaffold implantation in STEMI patientsResults from PRAGUE-19 study.Int J Cardiol,2016,209:20-21.
• [9]Fam JM,Felix C,van Geuns RJ,et al.Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction:a propensitymatched comparison to metallic drug eluting stents 18-month followup of the BVS STEMI fi rst study.Euro Intervention,2016,12(1):30-37.
• [10]Brugaletta S,Gori T,Low AF,et al.Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in STsegment elevation myocardial inf arction:1-year results of a propensity score matching comparison:the BVS-EXAMINATION Study(bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).JACC Cardiovasc Interv,2015,8(1 Pt B):189-197.
• [11]Brugaletta S,Gori T,Low AF,et al.ABSORB bioresorbable vascular scaffold vs.everolimus-eluting metallic stent in ST-segment elevation myocardial infarction(BVS EXAMINATION study):2-Year results from a propensity score matched comparison.Int J Cardiol,2016,214:483-448.
• [12]Sabate M,Windecker S,Iniguez A,et al.Everolimus-eluting bioresorbable stent vs.durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction:results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.Eur Heart J,2016,37(3):229-240.
• [13]Jimenez VA,Iniguez A,Baz JA,et al.A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes:The CENTURY II high risk ACS substudy.Cardiovasc Revasc Med,2016,17(6):355-361.
• [14]Chakraborty R,Patra S,Banerjee S,et al.Outcome of everolimus eluting bioabsorbable vascular scaffold(BVS)compared to non BVS drug eluting stent in the management of ST-segment elevation myocardial infarction(STEMI)-A comparative study.Cardiovasc Revasc Med,2016,17(3):151-154.
• [15]Cortese B,Ielasi A,Romagnoli E,et al.Clinical comparison with short-term f ollow-up of bioresorbable vascular scaff old versus everolimus-eluting stent in primary percutaneous coronary interventions.Am J Cardiol,2015,116(5):705-710.
• [16]Otsuka F,Vorpahl M,Nakano M,et al.Pathology of secondgeneration everolimus-eluting stents versus fi rst-generation sirolimusand paclitaxel-eluting stents in humans.Circulation,2014,129(2):211-223.
• [17]于一,赵迎新,史冬梅,等.生物可吸收支架的最新研究进展.中国介入心脏病学杂志,2016,24(9):521-525.
• [18]Kang SH,Chae IH,Park JJ,et al.Stent thrombosis with drugeluting stents and bioresorbable scaffolds:evidence from a network Meta-analysis of 147 trials.JACC Cardiovasc Interv,2016,9(12):1203-1212.
• [19]Bourantas CV,Papafaklis MI,Garcia-Garcia HM,et al.Shortand long-term implications of a bioresorbable vascular scaffold implantation on the local endothelial shear stress patterns.JACC Cardiovasc Interv,2014,7(1):100-101.
• [20]Karanasos A,Van Mieghem N,Van Ditzhuijzen N,et al.Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis:single-center experience.Circ Cardiovasc Interv,2015,8(5):pii:e002369.
• [21]von Birgelen C,Basalus MW.Oversized post-dilatation of current bioresorbable vascular scaffolds:kill or cure?Euro Intervention,2016,11(12):1330-1333.
• [22]Cortese B,Piraino D,Ielasi A,et al.Very late bioresorbable vascular scaffold thrombosis due to late device recoil.Int J Cardiol,2015,189:132-133.
• [23]Timmers L,Stella PR,Agostoni P.Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy.Eur Heart J,2015,36(6):393.